The legislation specifically addresses the management of prescription medications for treating alcohol and opioid use disorders. Notably, it forbids insurers from requiring a review for medicines used in these treatments, including Methadone, Buprenorphine, or Naltrexone. This move is aimed at reducing hurdles for patients seeking treatment for substance use disorders, highlighting the state's commitment to combatting the opioid crisis and facilitating access to necessary medical therapies.
Summary
Senate Bill S0687, known as the Benefit Determination and Utilization Review Act, seeks to amend existing insurance laws in Rhode Island significantly. The bill prohibits health care insurers from conducting retrospective reviews of coverage for health services when prior approval has been granted, except in cases where fraudulent or materially inaccurate information was used. This aims to protect patients from denial of coverage after services have been rendered and approved, thereby supporting continuity of care and safeguarding patient rights within the healthcare system.
Contention
While the bill received unanimous support during voting, with 34 yeas and no nays on May 30, 2023, there are potential points of contention regarding the implications for insurers. Concerns may arise around the financial impact on insurance providers, as limiting their ability to conduct reviews could lead to increased costs. Additionally, debates may emerge on how the bill will influence the quality and oversight of care provided, particularly as it relates to the rising opioid epidemic.
Hospital and Medical Services Utilization Review Act; requiring utilization review organization that uses AI to adhere to requirements; prohibiting AI from making certain determinations. Effective date.
Relates to the use of artificial intelligence by insurers and clinical peer reviewers for utilization review; establishes additional notice requirements for adverse determinations.
Relates to the use of artificial intelligence by insurers and clinical peer reviewers for utilization review; establishes additional notice requirements for adverse determinations.